Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study
Movement Disorders · 2024-03 · 39 (3) · 613-618
DOI: 10.1002/mds.29713 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 05.02.2024. Verfasst von Peter A LeWitt und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Wayne State University School of Medicine and Henry Ford Hospital, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Dyskinesia, Drug-Induced, Parkinson Disease, Tryptamines, Oxazolidinones. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Bukwang Pharmaceutical Co., Ltd.
Abstract (Originalsprache)
Background
Preclinical evidence suggests that co‐administration of the 5‐HT 1A agonist buspirone and the 5‐HT 1B/1D agonist zolmitriptan act synergistically to reduce dyskinesia to a greater extent than that achieved by either drug alone.
Objectives
Assess the therapeutic potential of a fixed‐dose buspirone and zolmitriptan combination in Parkinson's disease (PD) patients with levodopa‐induced dyskinesia.
Methods
Single‐center, randomized, placebo‐controlled, two‐way crossover study (NCT02439203) of a fixed‐dose buspirone/zolmitriptan regimen (10/1.25 mg three times a day) in 30 patients with PD experiencing at least moderately disabling peak‐effect dyskinesia.
Results
Seven days of treatment with buspirone/zolmitriptan added to levodopa significantly reduced dyskinesia as assessed by Abnormal Involuntary Movement Scale scores versus placebo (mean treatment effect vs. placebo: −4.2 [−6.1, −2.3]) without significantly worsening Unified Parkinson's Disease Rating Scale (UPDRS) Part III (ON) scores (mean treatment effect vs. placebo: 0.6 [−0.1, 1.3]). No serious adverse events were reported.
Conclusions
In this proof‐of‐concept study, addition of buspirone/zolmitriptan to the patients’ PD medication regimen significantly reduced dyskinesia severity without worsening motor function. © 2024 International Parkinson and Movement Disorder Society.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Wayne State University School of Medicine and Henry Ford Hospital, Detroit, Michigan, USA.
- Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA.
- Contera Pharma A/S, Hørsholm, Denmark.
- Bukwang Pharmaceutical Co., Ltd, Seoul, South Korea.
- Farmovs, Bloemfontein, South Africa.
ORCID-Profile: Peter A LeWitt, Kenneth Vielsted Christensen
Förderung
- Bukwang Pharmaceutical Co., Ltd
Zitieren
APA
LeWitt, P. A., Stebbins, G. T., Christensen, K. V., Tan, R., Pretorius, A., & Thomsen, M. (2024). Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study. Movement Disorders, 39(3), 613-618. https://doi.org/10.1002/mds.29713
Vancouver
LeWitt PA, Stebbins GT, Christensen KV, Tan R, Pretorius A, Thomsen M. Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study. Movement Disorders. 2024;39(3):613-618. doi:10.1002/mds.29713
BibTeX
@article{LeWitt2024,
author = {LeWitt, Peter A and Stebbins, Glenn T and Christensen, Kenneth Vielsted and Tan, Riswanto and Pretorius, Anél and Thomsen, Mikael},
title = {Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study},
journal = {Movement Disorders},
year = {2024},
volume = {39},
number = {3},
pages = {613--618},
doi = {10.1002/mds.29713}
}
EUVIMED